Vericel (VCEL)
(Delayed Data from NSDQ)
$46.91 USD
+1.15 (2.51%)
Updated Jun 27, 2024 04:00 PM ET
After-Market: $46.92 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Vericel Corporation (VCEL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$55.00 | $57.00 | $53.00 | 17.25% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Vericel Corporation comes to $55.00. The forecasts range from a low of $53.00 to a high of $57.00. The average price target represents an increase of 17.25% from the last closing price of $46.91.
Analyst Price Targets (7 )
Broker Rating
Vericel Corporation currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | Cowen & Co. | Joshua T Jennings | Not Available | Strong Buy |
5/8/2024 | SVB Securities | Michael Kratky | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Samuel E Brodovsky | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
1/16/2024 | Stephens | George Sellers | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $55.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | -0.10 |